Startup profile for Genesis Therapeutics: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Genesis Therapeutics funding, valuation and investors

AI molecular discovery company for small-molecule drug design (now Genesis Molecular AI).

Keep track of Genesis Therapeutics

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series B

$200M · August 2023

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$252M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series b

Investors in latest funding

Lead: Andreessen Horowitz , Menlo Ventures

Sources: latest funding Last verified: 2026-07-25

Overview

Genesis Therapeutics (now rebranded as Genesis Molecular AI) builds the GEMS platform — combining generative AI, predictive models, and physics-based simulation to discover small-molecule drug candidates for difficult protein targets.

Why Genesis Therapeutics is interesting

Genesis pioneered physics-informed generative AI for drug discovery; a16z led seed and co-led a $200M Series B with Menlo Ventures before the company rebranded to Genesis Molecular AI.

Product & use cases

Genesis Therapeutics (now Genesis Molecular AI) builds GEMS — generative AI plus physics simulation for small-molecule drug design.

  • Small-molecule design for difficult targets
  • Pharma partnership programs
  • Foundation model molecular space exploration

Key facts

  • Series A (2020): $52M led by Rock Springs with Menlo Ventures (/fund/menlo-ventures) and a16z seed lead (BioSpace)
  • Series B (Aug 2023): $200M co-led by a16z Bio+Health (/fund/andreessen-horowitz) and Menlo Ventures (BusinessWire)
  • Rebranded to Genesis Molecular AI; pharma deals with Genentech and Eli Lilly

Funding history (newest first)

Series B

2023-08 $200M

Source: https://www.businesswire.com/news/home/20230815000000/en/Genesis-Therapeutics-Raises-200M-Series-B

Series A

2020 $52M

Source: https://www.biospace.com/article/genesis-therapeutics-raises-52m-series-a/

Investors in our directory

Funds linked from Genesis Therapeutics's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz Menlo Ventures

Competitive landscape

Edge: Early mover in physics-informed generative AI for drug discovery; $200M Series B and pharma partnerships.

Genesis pioneered physics-informed generative models before rebranding. See /startup/genesis-molecular-ai for current entity name.

  • Recursion direct

    AI drug discovery platform; Genesis focused on generative small molecules.

  • Isomorphic Labs direct

    AI-native drug design from DeepMind lineage.

  • Relay Therapeutics adjacent

    Computationally driven drug discovery; different modality focus.

Notable stories

  • Rebranded to Genesis Molecular AI — both directory entries refer to the same company.
  • a16z led seed and co-led $200M Series B (2023).

Industries

Biotech & Life Sciences AI & Machine Learning

FAQs about Genesis Therapeutics

Practical answers founders, operators, and investors typically search for.

Genesis Therapeutics (now Genesis Molecular AI) developed the GEMS platform for AI-driven small-molecule drug discovery.
a16z (/fund/andreessen-horowitz) led seed and co-led $200M Series B with Menlo Ventures (/fund/menlo-ventures).
No — rebranded to Genesis Molecular AI. See /startup/genesis-molecular-ai.
Genesis Exploration of Molecular Space — generative AI plus physics-based simulation platform.
Series B — $200M in August 2023 before rebrand.
Genentech (2020) and Eli Lilly (2022) partnerships publicly disclosed.
Both use AI for drug discovery; Genesis focused on generative small-molecule design with physics simulation.
To reflect focus on foundation models for molecular AI rather than traditional biotech naming.
No — private, operating as Genesis Molecular AI.
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.